Three medical journals are investigating possible manipulation of data in heart studies led by researchers from Temple University that found favorable health impacts of blood thinners.
Julius Bogdan, vice president and general manager of the Healthcare Information and Management Systems Society (HIMSS) Digital Health Advisory Team for North America, explains the use of artificial intelligence (AI) algorithms to help address health disparities and the rise of healthcare consumerism.
CBD is generally viewed as a safe, well-tolerated treatment option, but there is still limited research on how it interacts with other medications commonly prescribed by cardiologists.
Julius Bogdan, vice president and general manager of the Healthcare Information and Management Systems Society (HIMSS) Digital Health Advisory Team for North America, discusses how artificial intelligence (AI) can help combat clinician burnout.
Comparison of flurpiridaz F-18 PET, SPECT and angiography of the 60-year-old female patients in the Aurora trial. The SPECT scan appeared normal, but flurpiridaz was shown to be more sensitive and showed the ischemia from two blockages in the right coronary artery. The new radiotracer may help expand cardiac PET.
The biggest news from the American Society of Nuclear Cardiology (ASNC) 2022 meeting was positive late-breaking data on the phase 3 Aurora trial for the flurpiridaz (F-18) PET radiotracer agent.
Three transcatheter tricuspid valve repair and replacement (TTVR) technologies that will likely see FDA clearance in. the next couple years include the Edwards Lifesciences Evoque transcatheter tricuspid valve (top left), Abbott TriClip (below) and the Edwards Lifesciences Pascal clip device (right).
The complexity of the mitral valve has slowed development of new transcatheter technologies, and it now seems much more likely that transcatheter devices for tricuspid valve will push ahead to gain FDA clearances.
The FDA has approved a clinical trial to evaluate the safety and efficacy of a new type of ablation catheter for patients with ventricular tachycardia (VT) resistant to conventional anti-arrhythmic drugs or standard ablation procedures.
Rebecca T. Hahn, MD, Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center, discusses some of the trends in the growing use of interventional echocardiographic guidance in transcatheter structural heart procedures.
